Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShort-Term Debt repayments
Ratios

Cue Biopharma (CUE) Short-Term Debt repayments (2023 - 2025)

Cue Biopharma's Short-Term Debt repayments history spans 3 years, with the latest figure at -$1.0 million for Q3 2025.

  • For Q3 2025, Short-Term Debt repayments changed 0.0% year-over-year to -$1.0 million; the TTM value through Sep 2025 reached -$4.0 million, changed 0.02%, while the annual FY2024 figure was -$4.0 million, 99.95% down from the prior year.
  • Short-Term Debt repayments for Q3 2025 was -$1.0 million at Cue Biopharma, roughly flat from -$1.0 million in the prior quarter.
  • Across five years, Short-Term Debt repayments topped out at -$999000.0 in Q4 2024 and bottomed at -$1.0 million in Q3 2023.
  • The 3-year median for Short-Term Debt repayments is -$1.0 million (2023), against an average of -$999888.9.
  • The largest YoY upside for Short-Term Debt repayments was 0.1% in 2024 against a maximum downside of 0.0% in 2024.
  • A 3-year view of Short-Term Debt repayments shows it stood at -$1.0 million in 2023, then grew by 0.1% to -$999000.0 in 2024, then fell by 0.1% to -$1.0 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Short-Term Debt repayments are -$1.0 million (Q3 2025), -$1.0 million (Q2 2025), and -$1.0 million (Q1 2025).